| Jul 1 |
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
|
| Jun 28 |
AbbVie, Genmab blood cancer therapy endorsed in EU
|
| Jun 28 |
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
|
| Jun 27 |
Completion of Share Buy-back Program
|
| Jun 27 |
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
|
| Jun 27 |
Genmab, AbbVie win FDA nod for relapsed follicular lymphoma therapy
|
| Jun 26 |
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
|
| Jun 20 |
10 Analysts Assess Genmab: What You Need To Know
|
| Jun 18 |
Capital Increase in Genmab as a Result of Employee Warrant Exercise
|
| Jun 11 |
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
|
